重磅肺癌新药古巴诞生记:革命时期的浪漫

2016-08-26 佚名 药明康德

米克·菲尔普斯(Mick Phillips)是一名美国威斯康星州的普通居民。2009年的秋天,他开始了剧烈的咳嗽。起初他以为只是偶受风寒,然而诊断的结果却是3期肺癌。米克立即接受了放疗与化疗,然而他的医生告诉他,每一轮治疗的效果都会逐渐下降。医生没有告诉他的是,按照疾病统计的数据,他的时日已剩下不多。米克做出了一个谁也没想到的选择:前往古巴。提到古巴,很多人可能想到的是雪茄、卡斯特罗、海岛

米克·菲尔普斯(Mick Phillips)是一名美国威斯康星州的普通居民。2009年的秋天,他开始了剧烈的咳嗽。起初他以为只是偶受风寒,然而诊断的结果却是3期肺癌。米克立即接受了放疗与化疗,然而他的医生告诉他,每一轮治疗的效果都会逐渐下降。医生没有告诉他的是,按照疾病统计的数据,他的时日已剩下不多。

米克做出了一个谁也没想到的选择:前往古巴。

提到古巴,很多人可能想到的是雪茄、卡斯特罗、海岛风光以及中国女排曾经的强劲对手。不过,你可能不知道的是,古巴拥有极为成熟的生物制药产业。因为遭受美国的经济贸易制裁,古巴难以获得先进的医疗药品,这也促使古巴白手起家,建立起自己的生物制药产业。在上世纪90年代,古巴分子免疫中心(Centro de Inmunología Molecular, CIM)在哈瓦那建立。经过多年的发展,CIM开发的非小细胞肺癌(NSCLC)的创新疗法CimaVax已成为了古巴生物制药产业最著名的成就之一。

CimaVax是一种疫苗,它的雏形出现于上世纪80年代,甚至早于CIM的建立。当时,科学家们正在研究表皮生长因子(EGF)通路,它正是癌细胞不受控制的增生原因之一。科学家们意识到,当EGF与细胞表面的EGF受体结合后,就会刺激细胞增生。而癌细胞表面的EGF受体数量,是普通细胞上的千倍。

为了避免这两者间的结合,美国与欧洲的科学家们开发了一系列阻断EGF受体功能的新药。它们其中的一些已经顺利上市,用于治疗乳腺癌、结肠癌与肺癌。然而这些药物都有不小的副作用。

▲吉塞拉·冈萨雷斯博士(图片来源:CNN)

“我们为什么一定要去阻断受体,而不去阻断血液中的EGF呢?”曾参与CimaVax研发长达数十年的科学家吉塞拉?冈萨雷斯(Gisela Gonzalez)博士说道。

在这一新思路下,吉塞拉与她的同事们人工合成了EGF,并加以两种能激发免疫反应的免疫佐剂,造出了CimaVax疫苗。在小鼠和猴子的试验中,他们确认这类疫苗能激发免疫系统产生针对EGF的抗体,从而降低血液中的EGF含量,并阻断EGF与EGF受体的结合。用了这些新药的患癌动物,寿命都得到了有效的延长。

在1994年,10名患者接受了首批CimaVax的治疗,以测试这种创新疗法的安全性与有效性。在取得突破性的成功后,越来越多的患者开始使用CimaVax。在古巴进行的多项临床试验表明,对于那些血液中EGF水平上升的NSCLC患者,CIMAvax疗法能够显着延长他们存活的时间。其中20%的患者接受疫苗治疗后存活期超过5年,而对照组没有任何患者活得那么长。

时至今日,已有将近4000名患者接受了该疗法的治疗。目前,这种新型疫苗已在古巴、秘鲁与委内瑞拉上市,于欧盟和马来西亚的临床试验也正在有条不紊地进行中。

▲Roswell Park Cancer Institute免疫学系主任Kelvin Lee博士(图片来源:Roswell Park Cancer Institute)

“我们认为CimaVax非常令人兴奋,” 美国罗斯威尔帕克癌症研究所(Roswell Park Cancer Institute)免疫学系主任凯文?李(Kelvin Lee)教授说:“它价格低廉,施药方法简单,毒副作用很小。古巴的研究人员已经完成了一系列临床试验来证明它可以延长患者的生存时间。”

凯文甚至向美国FDA递交了申请,希望引进CimaVax在美国进行临床试验。如果申请成功,这将是第一例古巴生产的医药制品在美国进行的临床试验

而值得一提的是,CimaVax并非古巴在肺癌治疗上的唯一突破。2013年,一款叫做Vaxira的新药在古巴获批上市。这款新药能够特异性地靶向肺癌细胞上的NeuGcGM3受体,并激发人体免疫系统的活力,起到治疗非小细胞肺癌的作用。

“他们在古巴完成的一切令人不可思议。”西密歇根大学医学院免疫中心的负责人托马斯?罗斯坦教授说道。由于与CIM有着合作关系,他经常访问古巴。在这些旅程中,他熟知在美国的禁运下,这个国家进行新药研发的资源有多么稀缺,环境又有多么恶劣。

故事再回到米克。由于美国与古巴曾处于长期的禁运,他无法获取古巴的肺癌新药。因此,他不得不携带冷藏设备飞到古巴,购买药物,并飞回加拿大,通过检查不怎么严格的陆路回到美国,并驱车11个小时回到威斯康辛的家。

他这样长途跋涉,仅仅是因为想要获取一款有望延长自己生命的药物。

▲在古巴新药的帮助下,米克的病情已经得到了很好的控制(图片来源:STAT)

好在,米克的一切努力都是值得的。在经历了病情的复发后,他的主治医生认为他只有半年到一年可活,5年生存率为0%。而接受了CimaVax的治疗后,米克体内的肿瘤已经消失了。现年79岁的他甚至开玩笑说,他会死于其他的疾病,而不是肺癌。

“当时我没有任何理由相信古巴是一个正确的选择,但我也没有任何理由去阻止他们寻找生机,”米克的主治医生回忆说:“但他奇迹般地活到了现在。如果你相信上帝,那么这是神迹。如果你相信科学,那么这就是CimaVax的功劳。”

参考资料:

[1] Cuba announces breakthrough cancer drug

[2] From Cuba, a novel cancer treatment ; Patients circumvent embargo for drug

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=130425, encodeId=1ed91304255b, content=好文,从这里学习了好多新知识,新信息。赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sun Sep 18 16:59:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548888, encodeId=c335154888834, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Aug 28 05:03:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585908, encodeId=d52c15859084e, content=<a href='/topic/show?id=69ef383e3a5' target=_blank style='color:#2F92EE;'>#古巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38373, encryptionId=69ef383e3a5, topicName=古巴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc0017331210, createdName=zhangying8794, createdTime=Sun Aug 28 05:03:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105530, encodeId=9edf10553038, content=博士蜜汁微笑, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Sat Aug 27 13:01:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104861, encodeId=0d431048611f, content=这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Aug 26 16:55:00 CST 2016, time=2016-08-26, status=1, ipAttribution=)]
    2016-09-18 ylzr123

    好文,从这里学习了好多新知识,新信息。赞了!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=130425, encodeId=1ed91304255b, content=好文,从这里学习了好多新知识,新信息。赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sun Sep 18 16:59:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548888, encodeId=c335154888834, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Aug 28 05:03:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585908, encodeId=d52c15859084e, content=<a href='/topic/show?id=69ef383e3a5' target=_blank style='color:#2F92EE;'>#古巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38373, encryptionId=69ef383e3a5, topicName=古巴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc0017331210, createdName=zhangying8794, createdTime=Sun Aug 28 05:03:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105530, encodeId=9edf10553038, content=博士蜜汁微笑, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Sat Aug 27 13:01:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104861, encodeId=0d431048611f, content=这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Aug 26 16:55:00 CST 2016, time=2016-08-26, status=1, ipAttribution=)]
    2016-08-28 xxxx1054
  3. [GetPortalCommentsPageByObjectIdResponse(id=130425, encodeId=1ed91304255b, content=好文,从这里学习了好多新知识,新信息。赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sun Sep 18 16:59:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548888, encodeId=c335154888834, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Aug 28 05:03:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585908, encodeId=d52c15859084e, content=<a href='/topic/show?id=69ef383e3a5' target=_blank style='color:#2F92EE;'>#古巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38373, encryptionId=69ef383e3a5, topicName=古巴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc0017331210, createdName=zhangying8794, createdTime=Sun Aug 28 05:03:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105530, encodeId=9edf10553038, content=博士蜜汁微笑, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Sat Aug 27 13:01:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104861, encodeId=0d431048611f, content=这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Aug 26 16:55:00 CST 2016, time=2016-08-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=130425, encodeId=1ed91304255b, content=好文,从这里学习了好多新知识,新信息。赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sun Sep 18 16:59:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548888, encodeId=c335154888834, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Aug 28 05:03:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585908, encodeId=d52c15859084e, content=<a href='/topic/show?id=69ef383e3a5' target=_blank style='color:#2F92EE;'>#古巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38373, encryptionId=69ef383e3a5, topicName=古巴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc0017331210, createdName=zhangying8794, createdTime=Sun Aug 28 05:03:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105530, encodeId=9edf10553038, content=博士蜜汁微笑, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Sat Aug 27 13:01:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104861, encodeId=0d431048611f, content=这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Aug 26 16:55:00 CST 2016, time=2016-08-26, status=1, ipAttribution=)]
    2016-08-27 xiaotaiyang1

    博士蜜汁微笑

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=130425, encodeId=1ed91304255b, content=好文,从这里学习了好多新知识,新信息。赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sun Sep 18 16:59:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548888, encodeId=c335154888834, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Aug 28 05:03:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585908, encodeId=d52c15859084e, content=<a href='/topic/show?id=69ef383e3a5' target=_blank style='color:#2F92EE;'>#古巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38373, encryptionId=69ef383e3a5, topicName=古巴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc0017331210, createdName=zhangying8794, createdTime=Sun Aug 28 05:03:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105530, encodeId=9edf10553038, content=博士蜜汁微笑, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Sat Aug 27 13:01:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104861, encodeId=0d431048611f, content=这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Aug 26 16:55:00 CST 2016, time=2016-08-26, status=1, ipAttribution=)]
    2016-08-26 李东泽

    这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。

    0